Changchun BCHT Biotechnology Co., Ltd.

BCHT was founded in 2004, with the registered capital of RMB 130 million yuan. CCHT holds 46.15% of its shares and CCHT is the largest shareholder of ‘‘BCHT’’.

Dr. KONG Wei, the general manager of BCHT, has been engaged in the research of AIDS vaccine and other biological vaccines at Johns Hopkins University for a long time. He is also an academic leader, an evaluation expert of the National Natural Science Foundation of China, a “863 Plan” expert of Ministry of Science and Technology of the People’s Republic of China and an expert of Center for Drug Evaluation, NMPA. He once gained the national May 1 Labor Medal and the first ‘‘Outstanding Entrepreneurship Award’’ for Overseas Chinese Professionals granted by Overseas Chinese Affairs Office of the State Council. He was also honored as the winner of ‘‘special government allowance of the State Council’’ and was selected into the national ‘‘New Century Talents Project’’. 

‘‘BCHT’’ is Jilin Provincial Modern Vaccine Engineering Research Center, Jilin Provincial Vaccine Science and Technology Innovation Center and the Vaccine Engineering Research Center of Changchun National Bioindustry Base. In 2008, its leading product of varicella vaccine was launched, which has the longest term of validity in the world. This technology has reached the international advanced level and the current domestic market share is 35%. In 2020, its first exclusive freeze-dried nasal spray live attenuated influenza vaccine (LAIV) was launched in China, which was also a cooperative project of WHO influenza action plan.